CohBar Announces Changes to Its Board of Directors and R&D Leadership

MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. Read More